MyFinsight
Home
Blog
About
Contact
Proceeds from sale of
common stock, net of...
$10,995,387
Net cash provided by
financing activities
$10,995,387
Net increase
(decrease) in cash and cash...
$3,901,857
Canceled cashflow
$7,093,530
Stock-based compensation,
including the issuance of...
$2,195,516
Prepaids and other
current assets
-$578,196
Acquired in-process
research and development...
$10,000
Depreciation
$2,807
Net cash used in
operating activities
-$6,208,530
Net cash used in
investing activities
-$885,000
Canceled cashflow
$2,786,519
Other income
$433,227
Collaboration revenue
$251,147
Net loss
-$7,206,990
Purchase of in-process
research and development...
$885,000
Canceled cashflow
$684,374
Accrued expenses
-$1,382,199
Deferred collaboration
revenue
-$251,147
Accounts payable
-$154,713
Total research and
development expenses
$4,096,580
Total general and
administrative expenses
$3,781,977
In-process research and
development
$10,000
Depreciation
$2,807
Stock-based compensation
$1,759,868
Other general and
administrative expenses
$1,290,436
Employee related costs
$731,673
Back
Back
Cash Flow
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)
source: myfinsight.com